Lin Z, Zou S, Wen K
Front Immunol. 2024; 14:1255443.
PMID: 38288118
PMC: 10822999.
DOI: 10.3389/fimmu.2023.1255443.
Van Doren S
Biochem Soc Trans. 2022; 50(2):839-851.
PMID: 35343563
PMC: 10443904.
DOI: 10.1042/BST20210640.
Risso V, Lafont E, Le Gallo M
Cell Death Dis. 2022; 13(3):248.
PMID: 35301281
PMC: 8931059.
DOI: 10.1038/s41419-022-04688-x.
Nevi L, Costantini D, Safarikia S, Di Matteo S, Melandro F, Berloco P
Cells. 2019; 8(11).
PMID: 31731674
PMC: 6912632.
DOI: 10.3390/cells8111443.
Zhou Y, Wang X, Huang X, Li X, Cheng K, Yu H
CNS Neurosci Ther. 2019; 26(3):309-318.
PMID: 31710183
PMC: 7081167.
DOI: 10.1111/cns.13254.
Immunosenescence and lymphomagenesis.
Mancuso S, Carlisi M, Santoro M, Napolitano M, Raso S, Siragusa S
Immun Ageing. 2018; 15:22.
PMID: 30258468
PMC: 6151062.
DOI: 10.1186/s12979-018-0130-y.
Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C, Li J, Wang H, Song S
Oncotarget. 2016; 7(45):73971-73983.
PMID: 27738332
PMC: 5342028.
DOI: 10.18632/oncotarget.12605.
Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity.
Chang C, Tai J, Li S, Nishikawa T, Kaneda Y
Oncotarget. 2016; 7(27):42195-42207.
PMID: 27259252
PMC: 5173127.
DOI: 10.18632/oncotarget.9743.
Perforin, CD28 and CD95 expression in circulating CD4 and CD8 cells as predictors of head and neck (H&N) cancer patient survival.
Laytragoon-Lewin N, Jonson F, Lundgren J, Rutqvist L, Wikby A, Lofgren S
Med Oncol. 2014; 31(12):290.
PMID: 25344268
DOI: 10.1007/s12032-014-0290-3.
Actual status of therapeutic vaccination in non-small cell lung cancer.
Szyszka-Barth K, Ramlau K, Gozdzik-Spychalska J, Spychalski L, Bryl M, Golda-Gocka I
Contemp Oncol (Pozn). 2014; 18(2):77-84.
PMID: 24966788
PMC: 4068811.
DOI: 10.5114/wo.2014.42724.
Immune-checkpoint blockade and active immunotherapy for glioma.
Ahn B, Pollack I, Okada H
Cancers (Basel). 2013; 5(4):1379-412.
PMID: 24202450
PMC: 3875944.
DOI: 10.3390/cancers5041379.
New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.
Diefenbach C, Steidl C
Clin Cancer Res. 2013; 19(11):2797-803.
PMID: 23447000
PMC: 3928836.
DOI: 10.1158/1078-0432.CCR-12-3064.
Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.
Taliouri E, Vrekoussis T, Vergetaki A, Agorastos T, Makrigiannakis A
Tumour Biol. 2012; 34(1):125-30.
PMID: 23076876
DOI: 10.1007/s13277-012-0519-8.
Targeting T cells with bispecific antibodies for cancer therapy.
Lum L, Thakur A
BioDrugs. 2011; 25(6):365-79.
PMID: 22050339
PMC: 3792709.
DOI: 10.2165/11595950-000000000-00000.
Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.
Swindall A, Bellis S
J Biol Chem. 2011; 286(26):22982-90.
PMID: 21550977
PMC: 3123066.
DOI: 10.1074/jbc.M110.211375.
Overview of cellular immunotherapy for patients with glioblastoma.
Vauleon E, Avril T, Collet B, Mosser J, Quillien V
Clin Dev Immunol. 2010; 2010.
PMID: 20953324
PMC: 2952949.
DOI: 10.1155/2010/689171.
Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.
Yang C, Guh J, Teng C, Chen C, Chen P
Br J Pharmacol. 2009; 157(7):1175-85.
PMID: 19466993
PMC: 2743836.
DOI: 10.1111/j.1476-5381.2009.00237.x.
Immunotherapeutic approaches for glioma.
Okada H, Kohanbash G, Zhu X, Kastenhuber E, Hoji A, Ueda R
Crit Rev Immunol. 2009; 29(1):1-42.
PMID: 19348609
PMC: 2713019.
DOI: 10.1615/critrevimmunol.v29.i1.10.
Immunosenescence and cancer vaccines.
Provinciali M
Cancer Immunol Immunother. 2009; 58(12):1959-67.
PMID: 19198836
PMC: 11030101.
DOI: 10.1007/s00262-009-0665-z.
Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.
Gomez G, Hickey M, Tritz R, Kruse C
Gene Ther Mol Biol. 2008; 12(1):101-110.
PMID: 19066635
PMC: 2597650.